Photo by Mat Napo on Unsplash

Pfizer Inc, known by the ticker symbol PFE,  is a large-cap general drug manufacturer, operating in the healthcare business sector. This is my first report on PFE for this Viital stock portfolio. I last reviewed it on in October 9th 2020 when I selected it as the fifth pick for my Vista portfolio five. 

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; Arvinas, Inc.; and Syapse, Inc. 

Pfizer Inc. was founded in 1849 and is headquartered in New York, New York

Three key data points gauge any dividend equity or fund such as Pfizer Inc, (PFE):

(1) Price

(2) Dividends

(3) Returns

Those three basic keys best tell whether any company has made, is making, and will make money. 

PFE Price

Pfizer's price per share was $53.45 as of yesterday's market close. One year ago its price was $34.92. Therefore PFE's share price rose $18.53 or just over 53% in the past year.

If PFE's stock trades in the range of $30.00 to $60.00 this next year, its recent $53.45 share price might rise by $4.55 to reach $58.00  by February 8, 2023. This estimate is just seven cents under the median of one year target single share prices from 21 analysts tracking the stock for their brokerage houses.

PFE Dividends

Pfizer's most recent quarterly dividend of $0.40 will be paid to shareholders March 4th, to those on record as of January 27th.  The PFE estimated Annual dividend payout per share of $1.60 yields 2.99% per yesterday's $53.45. closing price. 

PFE has paid quarterly dividend payouts increasing annually since January,1986. That stretch marked 36 years last month.

PFE Returns

Adding the $1.60 annual estimated PFE forward-looking dividend to its estimated one-year share price upside of $4.55 shows a $6.15 potential gross gain, per share, to be reduced by any costs to trade PFE shares.  

At yesterday's $53.45 price per share, a little over $1000 would buy 19 shares.

A $10 broker fee (if charged) would be paid half at purchase and half at sale and might cost us about $0.53 per share.

Subtract that maybe $0.53 brokerage cost from my estimated $6.15 gross gain estimate per share results in a net gain of $5.62 X 19 shares = $106.78 for a 10.67% net gain on a $1.015.55 investment.

So it is that Pfizer Inc, (PFE) shows a possible 10.67% net gain including a 2.99% forward estimated dividend yield. 

Over the next year at this time our $1000 investment in Pfizer Inc, (PFE) could generate $29.90 in cash dividends alone. Note that a single share of PFE stock bought at yesterday's share price of $53.45 is nearly $24 more than the dividend income from $1000.00 invested. So, by my dogcatcher ideal, now is not the time to pickup Pfizer Inc, (PFE) shares. The estimated next-year dividend from $1K invested is $23.55 less than PFE's single share price. Consider yourself alerted. Its a sign!  Wait for PFE shares to pull back below $40.00.

All of the estimates above are speculation based on the past history of Pfizer Inc, (PFE). Only time and money invested in this stock will determine its market value.